De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sangamo Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Sangamo Therapeutics' is Sandy Macrae, benoemd in Jun2016, heeft een ambtstermijn van 8.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.39M, bestaande uit 29.9% salaris en 70.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 343.17K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 4.9 jaar.
Belangrijke informatie
Sandy Macrae
Algemeen directeur
US$2.4m
Totale compensatie
| Percentage CEO-salaris | 29.9% |
| Dienstverband CEO | 8.3yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 4.9yrs |
Recente managementupdates
Recent updates
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow
Sep 22Sangamo Therapeutics: Finding An Opportunity To Reload
Aug 21Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$250m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
Compensatie versus markt: De totale vergoeding ($USD 2.39M ) Sandy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.49M ).
Compensatie versus inkomsten: De vergoeding van Sandy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sandy Macrae (61 yo)
8.3yrs
Tenure
US$2,392,272
Compensatie
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$2.39m | 0.19% $ 326.4k | |
| Senior VP | 5.3yrs | US$1.06m | 0.036% $ 61.5k | |
| Senior VP & Chief Development Officer | 5.8yrs | US$1.03m | 0.044% $ 74.9k | |
| Head of Research | less than a year | geen gegevens | 0.014% $ 23.9k | |
| Head of Technology | less than a year | geen gegevens | geen gegevens | |
| Head of Corporate Communications & Investor Relations Officer | no data | geen gegevens | geen gegevens | |
| Senior VP | 3.2yrs | geen gegevens | 0.041% $ 70.7k | |
| Head of Technical Operations | 1.4yrs | geen gegevens | geen gegevens | |
| Head of Business Development & Alliance Management | less than a year | geen gegevens | geen gegevens | |
| Scientist II - Discovery & Translational Research | no data | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SGMO wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$2.39m | 0.19% $ 326.4k | |
| Independent Chairwoman of the Board | 10.3yrs | US$99.28k | 0.030% $ 51.6k | |
| Independent Director | 8.3yrs | US$80.53k | 0.024% $ 40.9k | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Independent Director | 6.3yrs | US$76.78k | 0.025% $ 42.9k | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.9yrs | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
66.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SGMO wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).